Latest Insider Transactions at Aurinia Pharmaceuticals Inc. (AUPH)
This section provides a real-time view of insider transactions for Aurinia Pharmaceuticals Inc. (AUPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aurinia Pharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aurinia Pharmaceuticals Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2022
|
Michael Robert Martin Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+11.67%
|
-
|
|
Jan 03
2022
|
Joseph P Hagan Director |
SELL
Open market or private sale
|
Direct |
40,000
-52.92%
|
$880,000
$22.94 P/Share
|
|
Jan 03
2022
|
Joseph P Hagan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+47.9%
|
$200,000
$5.08 P/Share
|
|
Dec 13
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Direct |
1,600
+23.19%
|
$32,000
$20.04 P/Share
|
|
Nov 11
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-53.39%
|
$2,800,000
$28.89 P/Share
|
|
Nov 11
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+34.81%
|
$500,000
$5.3 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,000
-16.45%
|
$319,000
$29.5 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
29,000
-30.25%
|
$812,000
$28.82 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,000
+23.23%
|
$522,000
$18.38 P/Share
|
|
Nov 10
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-29.16%
|
$3,000,000
$30.86 P/Share
|
|
Nov 10
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+22.3%
|
$500,000
$5.68 P/Share
|
|
Nov 10
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
60,000
-26.21%
|
$1,800,000
$30.91 P/Share
|
|
Nov 09
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,000
-36.42%
|
$1,500,000
$30.17 P/Share
|
|
Nov 09
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-28.27%
|
$1,500,000
$30.17 P/Share
|
|
Nov 01
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-20.28%
|
$1,395,000
$31.64 P/Share
|
|
Nov 01
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+16.86%
|
$135,000
$3.2 P/Share
|
|
Nov 01
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.68%
|
$1,395,000
$31.64 P/Share
|
|
Nov 01
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+19.8%
|
$225,000
$5.3 P/Share
|
|
Oct 25
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
130,000
-66.42%
|
$3,770,000
$29.75 P/Share
|
|
Oct 25
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
95,000
+32.68%
|
$285,000
$3.2 P/Share
|
|
Sep 21
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
32,500
-12.71%
|
$747,500
$23.86 P/Share
|
|
Sep 21
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
27,136
+9.65%
|
$54,272
$2.92 P/Share
|
|
Sep 21
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
87,500
-33.1%
|
$2,100,000
$24.02 P/Share
|
|
Sep 21
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
87,500
+9.71%
|
$787,500
$9.91 P/Share
|
|
Sep 20
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
28,500
-7.19%
|
$598,500
$21.66 P/Share
|
|
Sep 20
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,500
+12.19%
|
$142,500
$5.3 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
44,000
-10.42%
|
$924,000
$21.76 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
134,000
+15.97%
|
$536,000
$4.6 P/Share
|
|
Sep 14
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
22,500
-17.5%
|
$472,500
$21.75 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
90,000
-33.73%
|
$1,890,000
$21.19 P/Share
|
|
Sep 13
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+34.3%
|
$450,000
$3.2 P/Share
|
|
Sep 13
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+11.02%
|
$125,000
$5.3 P/Share
|
|
Sep 10
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
150,000
-52.21%
|
$2,850,000
$19.84 P/Share
|
|
Sep 10
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
10,000
-3.68%
|
$190,000
$19.8 P/Share
|
|
Sep 10
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
25,000
-12.38%
|
$475,000
$19.8 P/Share
|
|
Sep 07
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
5,000
-3.48%
|
$90,000
$18.3 P/Share
|
|
Sep 07
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-4.07%
|
$135,000
$18.1 P/Share
|
|
Aug 26
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
22,500
-10.88%
|
$382,500
$17.81 P/Share
|
|
Aug 25
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.51%
|
$75,000
$15.85 P/Share
|
|
Aug 09
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.36%
|
$80,000
$16.01 P/Share
|
|
Aug 09
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.03%
|
$720,000
$16.03 P/Share
|
|
Jul 28
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.31%
|
$65,000
$13.86 P/Share
|
|
Jun 22
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.25%
|
$65,000
$13.76 P/Share
|
|
May 12
2021
|
R. Hector Mac Kay Dunn |
BUY
Open market or private purchase
|
Direct |
3,000
+22.6%
|
$33,000
$11.27 P/Share
|
|
May 11
2021
|
R. Hector Mac Kay Dunn |
BUY
Open market or private purchase
|
Direct |
1,500
+22.5%
|
$16,500
$11.16 P/Share
|
|
May 11
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Direct |
2,500
+40.32%
|
$25,000
$10.96 P/Share
|
|
May 11
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+8.27%
|
$60,000
$3.02 P/Share
|
|
May 11
2021
|
Peter Greenleaf Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,125
+17.57%
|
$51,250
$10.63 P/Share
|
|
May 11
2021
|
Matthew Maxwell Donley Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
9,900
+50.0%
|
$99,000
$10.07 P/Share
|
|
May 11
2021
|
Joseph M Miller Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$9,000
$9.74 P/Share
|